Tumor Inhibition by Using Chitosan: siRNA PDGFR-β in Breast Cancer Model of Rat

被引：0
|
作者：
Akbuga, Julide [1 ]
Turan, Suna Ozbas [1 ]
Salva, Emine [2 ]
Ozkan, Naziye [3 ]
Kabasakal, Levent [4 ]
Alan, Saadet [5 ]
机构：
[1] Marmara Univ, Pharmaceut Biotechnol, Istanbul, Turkey
[2] Inonu Univ, Pharmaceut Biotechnol, Malatya, Turkey
[3] Marmara Univ, Pathol, Istanbul, Turkey
[4] Marmara Univ, Pharmacol, Istanbul, Turkey
[5] Malatya State Hosp, Med Pathol, Malatya, Turkey
来源：
MOLECULAR THERAPY | 2016年 / 24卷
关键词：
D O I：
10.1016/S1525-0016(16)32961-6
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
152
引用
收藏
页码：S60 / S60
页数：1
相关论文
共 50 条
  • [41] siRNA targeting Livin decreases tumor in a xenograft model for colon cancer
    Oh, Bo-Young
    Lee, Ryung-Ah
    Kim, Kwang Ho
    WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 17 (20) : 2563 - 2571
  • [42] Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR β signalling
    Weigel, Marion T.
    Meinhold-Heerlein, No
    Bauerschlag, Dirk O.
    Schem, Christian
    Bauer, Maret
    Jonat, Walter
    Maass, Nicolai
    Mundhenke, Christoph
    CANCER LETTERS, 2009, 273 (01) : 70 - 79
  • [43] In Vitro PDGF-B Gene Silencing Studies and In Vivo Delivery of siRNA to the Rat Kidney Using Chitosan/siRNA Nanoplexes
    Salva, Emine
    Ozbas Turan, Suna
    Alan, Saadet
    Akbuga, Julide
    MARMARA PHARMACEUTICAL JOURNAL, 2016, 20 (03) : 263 - 268
  • [44] Bcl 2 and Bcl-xL are candidate targets for growth inhibition of breast cancer cells using siRNA lipoplexes
    Sidi, Yechezkel
    Yakobson, Emanuel
    Vestin, Assaf
    Sergeyev, Victoria
    Khazanov, Elena
    Barenholz, Yehezkel
    CANCER RESEARCH, 2006, 66 (08)
  • [45] MRI monitoring of tumor response following anglogenesis inhibition in an experimental human breast cancer model
    Turetschek, K
    Preda, A
    Floyd, E
    Shames, DM
    Novikov, V
    Roberts, TPL
    Wood, JM
    Fu, YJ
    Carter, WO
    Brasch, RC
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (03) : 448 - 455
  • [46] Inhibition Effect of siRNA-Downregulated UHRF1 on Breast Cancer Growth
    Yan, Feng
    Tan, Xu-Yan
    Geng, Yao
    Ju, Huang-Xian
    Gao, Yan-Fang
    Zhu, Ming-Chen
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2011, 26 (02) : 183 - 189
  • [47] Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis
    Sun, Ping
    Huang, Wei
    Jin, Mingji
    Wang, Qiming
    Fan, Bo
    Kang, Lin
    Gao, Zhonggao
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2016, 11 : 4931 - 4945
  • [48] MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model
    Karl Turetschek
    Anda Preda
    Eugenia Floyd
    David M. Shames
    Viktor Novikov
    Timothy P. Roberts
    Jeanette M. Wood
    Yanjun Fu
    Wayne O. Carter
    Robert C. Brasch
    European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30 : 448 - 455
  • [49] A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β
    Clinton Yam
    Rashmi K. Murthy
    Gaiane M. Rauch
    James L. Murray
    Ronald S. Walters
    Vicente Valero
    Abenaa M. Brewster
    Robert C. Bast
    Daniel J. Booser
    Sharon H. Giordano
    Francisco J. Esteva
    Wei Yang
    Gabriel N. Hortobagyi
    Stacy L. Moulder
    Banu Arun
    Investigational New Drugs, 2018, 36 : 1103 - 1109
  • [50] A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-
    Yam, Clinton
    Murthy, Rashmi K.
    Rauch, Gaiane M.
    Murray, James L.
    Walters, Ronald S.
    Valero, Vicente
    Brewster, Abenaa M.
    Bast, Robert C., Jr.
    Booser, Daniel J.
    Giordano, Sharon H.
    Esteva, Francisco J.
    Yang, Wei
    Hortobagyi, Gabriel N.
    Moulder, Stacy L.
    Arun, Banu
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (06) : 1103 - 1109
12345